- Home
- ABBV
ABBV
AbbVie Inc.
as 08-29-2025 4:00pm EST
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | NORTH CHICAGO |
| Market Cap: | 365.1B | IPO Year: | N/A |
| Target Price: | $216.10 | AVG Volume (30 days): | 4.4M |
| Analyst Decision: | Buy | Number of Analysts: | 21 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 2.10 | EPS Growth: | -29.76 |
| 52 Week Low/High: | $163.81 - $218.66 | Next Earning Date: | 07-31-2025 |
| Revenue: | $58,328,000,000 | Revenue Growth: | 6.05% |
| Revenue Growth (this year): | 9.87% | Revenue Growth (next year): | 8.91% |
Stock Insider Trading Activity of AbbVie Inc. (ABBV)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SALEKI-GERHARDT AZITA | ABBV | EVP, CHIEF OPERATIONS OFFICER | Aug 12 '25 | Sell | $198.42 | 42,370 | $8,407,055.40 | 177,292 |
Latest AbbVie Inc. News
ABBV Breaking Stock News: Dive into ABBV Ticker-Specific Updates for Smart Investing
Motley Fool
9 hours ago
The Smartest Dividend Stocks to Buy With $500 Right Now
Zacks
a day ago
ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025?
Zacks
a day ago
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
MT Newswires
a day ago
DBS Bank Adjusts Price Target on AbbVie to $208 From $188, Maintains Hold Rating
Pharmaceutical Technology
a day ago
Health Canada issues NOC to AbbVie’s upadacitinib for giant cell arteritis
Simply Wall St.
a day ago
Assessing AbbVie’s Valuation After $1.2B Bretisilocin Acquisition Announcement
Insider Monkey
a day ago
Genmab A/S (GMAB)’s Epcoritamab Delivers 95% Response in Lymphoma
Insider Monkey
a day ago
Genmab A/S (GMAB) Expands Tivdak and Epkinly Commercial Push Globally
Compare ABBV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ABBV AbbVie Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.